NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation

Eculizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID703]

Final Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Alexion Pharma UK (eculizumab)	Allied Health Professionals Federation
The state of the s	Association of Renal Industries
Patient/carer groups	Board of Community Health Councils in
Afiya Trust	Wales
aHUS UK	British National Formulary
Black Health Agency	Care Quality Commission
British Kidney Patient Association	Commissioning Support Appraisals Service
British Liver Trust	Department of Health, Social Services and
Children's Liver Disease Foundation	Public Safety for Northern Ireland
Contact a Family	Healthcare Improvement Scotland
Equalities National Council	Medicines and Healthcare products
Genetic Alliance UK	Regulatory Agency
Independent Age	National Association of Primary Care
Kidney Alliance	National Pharmacy Association
Kidney Research UK	NHS Alliance
Kids Kidney Research	NHS Commercial Medicines Unit
Muslim Council of Britain	NHS Confederation
Muslim Health Network	Scottish Medicines Consortium
National Kidney Federation	Welsh Government
Rare Disease UK	Welsh Kidney Patients Association
South Asian Health Foundation	Welsh Urological Society
Specialised Healthcare Alliance	
Together for Shorter Lives	Comparator manufacturers
Transplant Support Network	None
Professional groups	Relevant research groups
 Addenbrookes Liver Transplant 	Cochrane Renal Group
Association	Health Research Authority
aHUS ACTION	MRC Clinical Trials Unit
Association of Renal Industries	National Institute for Health Research
Association of Renal Technologists	Research Institute for the Care of Older
 Association of Surgeons of Great Britain and Ireland 	People
British Association for Paediatric	Evidence Review Group
Nephrology	School of Health Related and Related
British Association for Services to the Elderly	Research Technology Assessment Group (ScHARR-TAG)
British Association of Urological Nurses	National Institute for Health Research Health
British Association of Urological	Technology Assessment
Surgeons	

National Institute for Health and Care Excellence

Matrix for the evaluation of eculizumab for treating atypical haemolytic uraemic syndrome Issue date: July 2013

Consultees		Commentators (no right to submit or appeal)
•	British Geriatrics Society	Associated Guideline Groups
•	British Renal Society	National Clinical Guidelines Centre
•	British Society for Haematology	
•	British Transplantation Society	Associated Public Health Groups
•	NHS Blood and Transplant	Public Health England Public Health
•	Renal Association	Public Health Wales NHS Trust
•	Royal College of Anaesthetists	
•	Royal College of General Practitioners	
•	Royal College of Nursing	
•	Royal College of Paediatric and Child Health	
•	Royal College of Pathologists	
•	Royal College of Physicians	
•	Royal College of Surgeons	
•	Royal Pharmaceutical Society	
•	Royal Society of Medicines	
•	Society for DGH Nephrologists	
•	UK Renal Pharmacy Group	
•	United Kingdom Clinical Pharmacy	
	Association	
•	Urology Foundation	
<u>Others</u>		
•	Department of Health	
•	NHS England	
•	NHS Rotherham CCG	
•	NHS Surrey Downs CCG	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the recommendations.

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturer/sponsor commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the HST Evaluation Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Care Excellence Matrix for the evaluation of eculizumab for treating atypical haemolytic uraemic syndrome Issue date: July 2013

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.